Targeted alpha-therapy (TAT) is a promising strategy for disseminated malignancies such as Acute Myeloid Leukemia (AML), the most common and lethal leukemia in adults. Clinical trials with [225Ac]Ac-anti-CD33 monoclonal antibodies (mAbs) have shown encouraging responses, as CD33 is expressed in 85-90% of AML cases. However, its expression on committed myeloid progenitors and mature myeloid cells leads to severe toxicity, notably prolonged myelosuppression.
SORIN Mylene;
GOUARD Sebastian;
MARIONNEAU-LAMBOT S;
MAINGUENEAU C;
MORGENSTERN Alfred;
BRUCHERTSEIFER Frank;
CHEREL M.;
HADDAD Ferid;
ALLARD Mathilde;
GASCHET J;
2026-05-04
ELSEVIER INC.
JRC145583
1876-7982 (online),
https://www.sciencedirect.com/science/article/pii/S1939865426000470,
https://publications.jrc.ec.europa.eu/repository/handle/JRC145583,
10.1016/j.jmir.2026.102233 (online),
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Additional supporting files
| File name | Description | File type | |
|---|
